Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.

Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, Szekely L, Kärre K, Carbone E, Selivanova G.

Cell Cycle. 2011 Oct 1;10(19):3346-58. doi: 10.4161/cc.10.19.17630. Epub 2011 Oct 1.

PMID:
21941086
2.

Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.

Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A.

Cancer Res. 2011 Sep 15;71(18):5998-6009. doi: 10.1158/0008-5472.CAN-10-3211. Epub 2011 Jul 15.

3.

Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.

Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D, Paschen A.

Cancer Res. 2012 Jan 15;72(2):460-71. doi: 10.1158/0008-5472.CAN-11-1977. Epub 2011 Nov 18.

4.

Natural killer cell-mediated shedding of ULBP2.

Wang R, Sun PD.

PLoS One. 2014 Mar 10;9(3):e91133. doi: 10.1371/journal.pone.0091133. eCollection 2014.

5.

Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R from HIV-1 primary isolates.

Pham TN, Richard J, Gerard FC, Power C, Cohen ÉA.

J Virol. 2011 Dec;85(23):12254-61. doi: 10.1128/JVI.05835-11. Epub 2011 Sep 28. Erratum in: J Virol. 2012 Feb;86(3):1902.

6.

Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.

Sers C, Kuner R, Falk CS, Lund P, Sueltmann H, Braun M, Buness A, Ruschhaupt M, Conrad J, Mang-Fatehi S, Stelniec I, Krapfenbauer U, Poustka A, Schäfer R.

Int J Cancer. 2009 Oct 1;125(7):1626-39. doi: 10.1002/ijc.24557.

7.

Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.

Matusali G, Tchidjou HK, Pontrelli G, Bernardi S, D'Ettorre G, Vullo V, Buonomini AR, Andreoni M, Santoni A, Cerboni C, Doria M.

FASEB J. 2013 Jun;27(6):2440-50. doi: 10.1096/fj.12-223057. Epub 2013 Feb 8.

PMID:
23395909
8.

Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.

Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminskyy VO, Juhlin CC, Höög A, Bodin I, Svjatoha V, Larsson C, Zedenius J, Wennerberg J, Lundqvist A.

Clin Cancer Res. 2014 Nov 15;20(22):5733-44. doi: 10.1158/1078-0432.CCR-14-0291. Epub 2014 Sep 11.

9.

Human Natural Killer cell expression of ULBP2 is associated with a mature functional phenotype.

Brennan K, McSharry BP, Keating S, Petrasca A, O'Reilly VP, Keane J, Doherty DG, Gardiner CM.

Hum Immunol. 2016 Oct;77(10):876-885. doi: 10.1016/j.humimm.2016.06.018. Epub 2016 Jun 24.

PMID:
27349945
10.

DNA methyltransferase-3a interacts with p53 and represses p53-mediated gene expression.

Wang YA, Kamarova Y, Shen KC, Jiang Z, Hahn MJ, Wang Y, Brooks SC.

Cancer Biol Ther. 2005 Oct;4(10):1138-43. Epub 2005 Oct 1.

PMID:
16131836
11.

Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.

Park MJ, Bae JH, Chung JS, Kim SH, Kang CD.

Immunol Invest. 2011;40(4):367-82. doi: 10.3109/08820139.2010.551435. Epub 2011 Feb 11.

PMID:
21314289
12.

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.

Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP.

Int J Cancer. 2014 Jun 15;134(12):2829-40. doi: 10.1002/ijc.28609. Epub 2013 Nov 29.

13.

The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB.

Schmiedel D, Tai J, Yamin R, Berhani O, Bauman Y, Mandelboim O.

Elife. 2016 Mar 16;5. pii: e13426. doi: 10.7554/eLife.13426.

14.

Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.

Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A.

Int J Cancer. 2009 Apr 1;124(7):1594-604. doi: 10.1002/ijc.24098.

15.

p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells.

Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH.

J Exp Med. 2013 Sep 23;210(10):2057-69. doi: 10.1084/jem.20130783. Epub 2013 Sep 16.

17.

Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D.

Song H, Park H, Park G, Kim YS, Lee HK, Jin DH, Kang HS, Cho DH, Hur D.

Oncol Rep. 2014 Jul;32(1):425-30. doi: 10.3892/or.2014.3191. Epub 2014 May 16.

PMID:
24841552
18.

Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.

Rölle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Söderberg-Nauclér C, Cosman D, Kärre K, Cerboni C.

J Immunol. 2003 Jul 15;171(2):902-8.

19.

Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells.

Cheon S, Lee JH, Park S, Bang SI, Lee WJ, Yoon DY, Yoon SS, Kim T, Min H, Cho BJ, Lee HJ, Lee KW, Jeong SH, Park H, Cho D.

J Biol Chem. 2011 Apr 8;286(14):12049-55. doi: 10.1074/jbc.M110.159756. Epub 2011 Feb 14.

20.

RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.

Cao W, Xi X, Hao Z, Li W, Kong Y, Cui L, Ma C, Ba D, He W.

J Biol Chem. 2007 Jun 29;282(26):18922-8. Epub 2007 Apr 30.

Supplemental Content

Support Center